1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel).
Saved in:
| Title: | 1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel). |
|---|---|
| Authors: | Dirven, I.1 (AUTHOR), Bertels, C.1 (AUTHOR), Vounckx, M.1 (AUTHOR), Kessels, J.I.1 (AUTHOR), Vanlaer, N.1 (AUTHOR), Von Kemp, B.A.2 (AUTHOR), Fasolino, G.3 (AUTHOR), Awada, G.1 (AUTHOR), Neyns, B.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS975-S975. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189420061 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Dirven%2C+I%2E%22">Dirven, I.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bertels%2C+C%2E%22">Bertels, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vounckx%2C+M%2E%22">Vounckx, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kessels%2C+J%2EI%2E%22">Kessels, J.I.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vanlaer%2C+N%2E%22">Vanlaer, N.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Von+Kemp%2C+B%2EA%2E%22">Von Kemp, B.A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fasolino%2C+G%2E%22">Fasolino, G.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Awada%2C+G%2E%22">Awada, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Neyns%2C+B%2E%22">Neyns, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS975-S975. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189420061 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.2271 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S975 Titles: – TitleFull: 1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Dirven, I. – PersonEntity: Name: NameFull: Bertels, C. – PersonEntity: Name: NameFull: Vounckx, M. – PersonEntity: Name: NameFull: Kessels, J.I. – PersonEntity: Name: NameFull: Vanlaer, N. – PersonEntity: Name: NameFull: Von Kemp, B.A. – PersonEntity: Name: NameFull: Fasolino, G. – PersonEntity: Name: NameFull: Awada, G. – PersonEntity: Name: NameFull: Neyns, B. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
